Annual Report 2014 amfAR,The Foundation for AIDS Research

Contents

amfAR in 2014: Program Highlights 01

Grants, Fellowships, and Awards 04

Research Grants, Fellowships and Awards

TREAT Asia Grants and Awards

GMT Initiative Awards

Public Policy Awards

Financial Highlights 10

Leadership and Advisory Committees 12

Board of Trustees

Scientific Advisory Committee

Program Advisory Council

Management Group

amfAR, The Foundation for AIDS Research, is dedicated to ending the global AIDS epidemic through innovative research. amfAR in 2014: Program Highlights

At least two HIV-positive individuals have been successfully transplanted under this protocol, using donors with a genetic mutation conferring resistance to HIV infection.

• Dr. Rowena Johnston, amfAR vice president and director of research, and multiple amfAR grantees presented at the 20th International AIDS Conference (AIDS 2014) in Melbourne, Australia. Six of these researchers, Drs. Dan Barouch, Nicolas Chomont, Steven Deeks, Sharon Lewin, Deborah Persaud, and Ole Søgaard sat on a seven-member panel discussing the latest breakthroughs in HIV vaccine and cure research during the “Towards a Cure” press conference.

• Research studies make the greatest impact on the AIDS field and on the broader scientific community when they are Research published in peer-reviewed journals. In FY2014, close to 50 scientific publications resulted from amfAR-funded research. • The search for a cure for HIV/AIDS is at the center of amfAR’s research efforts, and in February 2014, the Foundation launched the Countdown to a Cure for AIDS initiative, aimed TREAT Asia at developing the scientific basis for a cure by 2020. The Countdown will intensify amfAR’s cure-focused HIV research • TREAT Asia (Therapeutics Research, Education, and AIDS program through strategic investments of $100 million over the Training in Asia) is a network of clinics, hospitals, and research next five years. institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments throughout Asia • amfAR awarded nearly $4 million to 16 teams of scientists and the Pacific. Facilitated by amfAR, TREAT Asia seeks to working collaboratively under the auspices of the amfAR strengthen HIV/AIDS care, treatment, and management skills Research Consortium on HIV Eradication (ARCHE). The grants among healthcare professionals through education and training enabled research teams in the United States, the United programs developed by experts in the region. Kingdom, the Netherlands, Finland, France, Germany, Spain, Sweden, Thailand, and Australia to explore a range of innovative • In FY2014, the TREAT Asia network launched a multi-site strategies aimed at eliminating HIV infection from the body, clinical study that addresses obstacles to treating hepatitis including characterizing and eradicating the viral reservoirs C among individuals co-infected with HIV in four countries: that present a major obstacle to a cure. Since its inception in Indonesia, Malaysia, Thailand, and Vietnam. The study aims 2010, ARCHE funding has supported the work of 86 research to develop a pilot model of care for treating hepatitis C in teams pursuing cure-focused studies at 51 institutions on resource-limited settings that can be replicated throughout five continents.

• amfAR also awarded 12 targeted grants totaling more than $2.15 million to leading researchers from around the world who are working on a variety of cutting-edge, cure-focused studies. These projects included research aimed at therapeutic vaccine development, expanding our understanding of latent viral reservoirs, and examining pharmacological and gene therapy approaches to curing HIV.

• Six researchers received Mathilde Krim Fellowships in Basic Biomedical Research, which provide funding for exceptional young scientists who are new to the field of HIV/AIDS research. The 2014 Krim Fellows—each of whom received $150,000—are working on projects focused on HIV cure and epidemiology and on vaccine and treatment development.

• In May 2014, amfAR held a think tank in Munich, Germany, titled “Research Toward a Cure for AIDS: Stem Cell-Based Therapies in the Context of a European Consortium.” The think tank led to the establishment of the European Project to TREAT Asia released easy-to-understand educational materials Guide and Investigate the Potential for HIV Cure by Stem Cell about hepatitis C and HIV co-infection as part of its new Transplantation (EPISTEM), which is being funded by amfAR. hepatitis C screening and treatment study.

2 1 the region, where treatment for the disease is costly and often inaccessible. In addition, TREAT Asia developed policy briefs, a fact sheet, and illustrated educational materials about hepatitis C and HIV co-infection, and held a regional meeting on improving access to hepatitis C treatment.

• The TREAT Asia Studies to Evaluate Resistance, Pediatrics (TASER-P) completed the core activities of a three-year study on how children and adolescents who have developed resistance to first-line antiretroviral therapy (ARV) respond and adhere to second-line treatment. TREAT Asia will continue to follow approximately 60 children who have developed resistance to second-line treatment for another two years in order to better understand which third-line ARVs will be most needed in the region. amfAR’s “Making AIDS History: From Science to Solutions” briefing was • TREAT Asia developed three videos on the sexual and reproductive held in the Kennedy Caucus Room of the Russell Senate Office Building. health and rights of women living with HIV that provide fictional examples of both positive and negative advice that HIV-positive pregnant women might receive from healthcare professionals. The • In FY2014, amfAR held two Capitol Hill briefings in videos are in Thai with English subtitles and are available on TREAT Washington, D.C. The first, co-sponsored with AVAC, the Asia’s webpage and its public YouTube channel. Center for Global Health Policy, and the International AIDS Vaccine Initiative, discussed the role of research in ending • TREAT Asia was well represented at AIDS 2014 in Melbourne, AIDS and highlighted new developments in HIV vaccine and Australia. TREAT Asia staff and network investigators participated prevention science. For the second briefing, titled “Making in pre-conference workshops on HIV pediatric and cure research. AIDS History: From Science to Solutions,” amfAR assembled During the main conference, Dr. Annette Sohn, amfAR vice president a line-up of influential speakers in the fields of HIV research and director of TREAT Asia, was invited to give oral presentations and policy to review recent progress in the fight against on key at-risk populations in Asia, non-communicable diseases in AIDS and chart a roadmap for ending the pandemic. Notable resource-limited settings, and pediatric and adolescent HIV. presenters included Dr. Jim Yong Kim, Kenneth Cole, Dr. Paul Farmer, Judy Woodruff, Michel Sidibé, Ambassador Deborah Birx, Douglas Brooks, Dr. Anthony Fauci, House Public Policy Democratic Leader Nancy Pelosi, Senator Tom Harkin, and Congressman Jim Himes, among others. • Through its Public Policy office in Washington, D.C., amfAR educates policymakers, the media, and the public about evidence- based policies to address HIV/AIDS in the U.S. and around the world. In FY2014, amfAR continued to promote rational AIDS-related GMT Initiative policies based on the most current scientific knowledge. • Since 2007, amfAR has been serving the HIV-related • The Public Policy office produced a number of opinion pieces, needs of gay men, other men who has sex with men, and issue briefs, special reports, and infographics addressing important transgender individuals (collectively, GMT) throughout domestic topics, such as funding for HIV/AIDS programs and the developing world through its GMT Initiative. The GMT research, Medicaid expansion’s effect on HIV health services, and Initiative works to help expand access to HIV education and HIV prevention among key populations, specifically transgender prevention services; support advocacy aimed at increasing individuals and black men who have sex with men. funding for prevention and treatment services; and end the stigma, discrimination, and violence that threaten the lives of • amfAR partnered with the Treatment Action Group (TAG) to issue GMT individuals and fuel the spread of HIV/AIDS. a report titled Filling the Gaps in the U.S. HIV Treatment Cascade: Developing a Community Driven Research Agenda, which outlines • In FY2014, amfAR awarded more than $900,000 to 32 research needed to improve outcomes on the domestic HIV community-led grassroots groups in Africa, the Asia-Pacific, treatment cascade and ensure more people are engaged and the Caribbean, Eastern Europe and Central Asia, and retained in HIV care. Latin America for a wide range of projects addressing HIV prevention, outreach, education, advocacy, testing, research, • amfAR produced a special report with AVAC outlining the need for and capacity building. a new approach to tracking HIV data in order to better guide the key decisions that shape the global AIDS response. The report, • The GMT Initiative made four awards as part of its Advocacy Data Watch: Closing a Persistent Gap in the AIDS Response, in Action program, which supports GMT-led community- updates amfAR and AVAC’s 2012 Action Agenda to End AIDS. based organizations that wish to influence the policies of

32 of which included interviews with amfAR spokespeople—were carried in numerous media outlets, including The New York Times, The Wall Street Journal, The Washington Post, and The Huffington Post, and news agencies such as the Associated Press, CNN, Bloomberg News, and Reuters.

• amfAR has long benefited from the voices and the visibility of a wide range of prominent public figures. In FY2014, celebrity supporters included amfAR Global Fundraising Chairman Sharon Stone, amfAR Ambassadors Cheyenne Jackson, Janet Jackson, Milla Jovovich, Liza Minnelli, and Michelle Yeoh, as well as Dame Shirley Bassey, Justin Bieber, Mary J. Blige, Jessica Chastain, Sofia Coppola, Alan Cumming, Willem Dafoe, Leonardo DiCaprio, Jane Fonda, Grace Jones, Heidi Klum, Julianna Margulies, Kylie Minogue, Aishwarya Rai and Abhishek Bachchan, Lana Del Rey, Michelle Rodriguez, Diana Ross, and Dita Von Teese, among Members of GMT Initiative grantee Asociación Silueta X combat many others. homophobia and transphobia in Guayaquil, Ecuador. • amfAR’s public information team produces a range of educational materials, program reports, and periodicals in an effort to governments and external donors. Ten awards were made communicate the Foundation’s message and the need for AIDS under its Evidence in Action program, which documents research. Its FY2014 publications included: Innovations, amfAR’s the impact of community-based programs, with the goal biannual newsletter; the TREAT Asia Report, which is distributed of evaluating and eventually scaling up the most workable widely to an international audience; and a monthly e-mail strategies for stopping the spread of HIV among GMT newsletter sent to more than 100,000 subscribers. individuals. Evidence in Action was developed with support • The Foundation vigorously expanded its social media presence in from ViiV Healthcare’s Positive Action Program and the Elton FY2014, reaching large numbers of people, including a younger John AIDS Foundation. demographic that is often less educated about HIV/AIDS. amfAR • In FY2014, the GMT Initiative published two reports as part regularly added content to its Facebook page, and live tweeted of its Lessons from the Front Lines series. Lessons from the and posted images on Instagram from fundraising and program Front Lines: Research Impact Analysis, outlines several of the events. At the end of FY2014, the Foundation had 58,000 likes most successful community-led research studies GMT Initiative on Facebook, 30,000 Twitter followers, and nearly 37,000 grantee partners have implemented to improve HIV testing, Instagram followers. treatment, and awareness. Lessons from the Front Lines: Trans Health and Rights, produced in collaboration with Global Action for Trans Equality (GATE), examines the challenges faced by 10 grantee partners—many of which are led by transgender individuals—and assesses their progress.

• The GMT Initiative also created a series of fact sheets in English, French, and Spanish on emerging HIV prevention technologies that explain each technology and serve as a tool to help GMT advocates push for the interventions’ increased availability worldwide.

• Throughout the year, articles that discussed how various HIV-related issues impacted the GMT Initiative grantee partners’ lives and work were posted on the GMT Initiative blog, Grassroots.

Public Information • amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of AIDS press coverage. Grammy Award-winning superstar Mary J. Blige performed at amfAR’s 2014 Inspiration Gala Articles and reports involving amfAR—many São Paulo. (Photo: Kevin Tachman)

43 2014 RESEARCH Programming stem cells with a chimeric antigen Viral reservoir dynamics after therapeutic receptor to eradicate HIV vaccination and cART interruption FELLOWSHIPS, GRANTS, Principal Investigator: Scott Kitchen, Ph.D. Principal Investigator: Felipe Garcia, M.D., Ph.D. AND AWARDS University of California, Los Angeles Consorci Institut D’Investigacins Biomèdiques Los Angeles, CA August Pi i Sunyer $300,000 Barcelona, Spain All projects listed below were awarded $180,0001 amfAR funding during the period October 1, Allogeneic stem cell transplant in HIV-1-infected individuals Reducing latent viral reservoirs in infant macaques 2013, through September 30, 2014. Principal Investigator: Javier Martinez-Picado, Principal Investigator: Nancy Haigwood, Ph.D. Ph.D. Oregon Health and Science University amfAR RESEARCH CONSORTIUM ON University Medical Center Utrecht Portland, OR HIV ERADICATION (ARCHE) Utrecht, Netherlands $179,7951 $591,209 Unmasking the latent HIV reservoir using Determining viral reservoir during hyperacute HIV Triggering innate immune responses in HIV humanized mice infection in PrEP participants eradication therapy Principal Investigator: Ramesh Akkina, Ph.D. Principal Investigator: Hiroyu Hatano, M.D. Principal Investigator: Jane Rasaiyaah, Ph.D. Colorado State University Regents of the University of California, San University College London Fort Collins, CO Francisco London, United Kingdom $250,837 San Francisco, CA $163,704 $180,0001 A functional cure of SIV in macaques: model for Testing cord blood units for CCR5-delta 32 ongoing ARCHE human trials Principal Investigator: Vanderson Rocha, M.D., Can therapeutic vaccination reduce viral Principal Investigator: Eric Arts, Ph.D. Ph.D. reservoirs in early cART treated HIV? Case Western Reserve University National Health Service Blood and Transplant, Principal Investigator: Mario Ostrowski, M.D. Cleveland, OH Cord Blood Banks University of Toronto transferred to The University of Western Ontario Oxford, United Kingdom Toronto, Onatrio, Canada London, Canada 1 $126,600 (contract) $177,776 $187,341 Impact of sex-based differences on HIV reservoir Genetic analysis of unspliced HIV RNA produced Microglia and HIV-1 latency size and immune activation during HDAC inhibitor therapy Principal Investigator: Paula Cannon, Ph.D. Principal Investigator: Eileen Scully, M.D., Ph.D. Principal Investigator: Sarah Palmer, Ph.D. University of Southern California Massachusetts General Hospital Westmead Millennium Institute for Medical Los Angeles, CA Boston, MA Research/University of Sydney $180,000 $254,930 Westmead, Australia Impact of early ART on SIV reservoirs $180,0001 Evaluating the threat posed by intact, non- Principal Investigator: Ann Chahroudi, M.D., Ph.D. induced proviruses Emory University Role of graft versus host in SIV clearance Principal Investigator: Robert F. Siliciano, M.D., Atlanta, GA following stem cell transplatation Ph.D. $180,000 Principal Investigator: Jonah Sacha, Ph.D. Johns Hopkins University Oregon Health and Science University Harnessing induced hematopoietic stem cells to Baltimore, MD Portland, OR identify HIV reservoirs $360,000 $179,9921 Principal Investigator: Benjamin K. Chen, M.D., Viro-immunological analyses of SHIV reservoirs in Ph.D. macaques undergoing aHSCT Persistence and fate of invisible U/A pairs in HIV-1 Icahn School of Medicine at Mount Sinai Principal Investigator: Guido Silvestri, M.D. proviral DNA New York, NY Emory University Principal Investigator: James Stivers, Ph.D. 180,000 Atlanta, GA Johns Hopkins University Baltimore, MD Identifying and targeting HIV persistence in T cell $180,000 $180,0001 subsets during ART Principal Investigator: Nicolas Chomont, Ph.D. Modulating inflammation for immune Vaccine and Gene Therapy Institute of Florida TARGETED RESEARCH GRANTS reconstitution and HIV eradication Port St. Lucie, FL Principal Investigator: Rafick-Pierre Sékaly, Ph.D. transferred to Université de Montréal 1Funded in part by the Foundation for AIDS and Vaccine and Gene Therapy Institute of Florida Montréal, Canada Immune Research (FAIR) Port St. Lucie, FL $584,118 Latent HIV in Kupffer cells transferred to Case Western Reserve University Safety and immunologic and virologic response to Principal Investigator: Ashwin Balagopal, M.D. Cleveland, OH HIV-CTL therapy in HIV infection Johns Hopkins University $179,935 Principal Investigator: Cynthia Gay, M.D. Baltimore, MD The University of North Carolina at Chapel Hill $176,333 Host and viral control of P-TEFb activation and Chapel Hill, NC HIV transcription elongation $58,338 Dissecting the role of the mTOR pathway in CD8 Principal Investigator: Blanton Tolbert, Ph.D. restriction of HIV persistence Case Western Reserve University Allogeneic stem cell transplantation and HIV-1 Principal Investigator: Cheryl Cameron, Ph.D. Cleveland, OH persistence Vaccine and Gene Therapy Institute of Florida $180,000 Principal Investigator: Timothy Henrich, M.D. Port St. Lucie, FL The Brigham and Women’s Hospital transferred to Case Western Reserve University Boston, MA Cleveland, OH $191,039 $180,0001 MATHILDE KRIM FELLOWS IN BASIC BIOMEDICAL RESEARCH Gender-specific differences affecting reactivation Understanding the HIV-APOBEC3G interaction to of latent HIV prevent HIV persistence Memory Tfh cell function correlates with bNAb Principal Investigator: Jonathan Karn, Ph.D. Principal Investigator: Richard D’Aquila, M.D. generation during HIV infection Case Western Reserve University Feinberg School of Medicine, Northwestern Fellow: Rafael Cubas, Ph.D. Cleveland, OH University Vaccine and Gene Therapy Institute Florida $222,156 Chicago, IL Port St. Lucie, FL $180,000 $149,886

54 Identification of transmitted viral determinants The Prince Charles Hospital, Sunshine Coast Hospital and Health Service, of HIV pathogenesis Brisbane, Queensland Nambour West, Queensland Fellow: Dario Dilernia, Ph.D. Diane Rowling David Sowden, M.B.B.S Emory University $4,9501 $7,5001 Atlanta, GA $150,000 Cairns Sexual Health Service, Northside Clinic (Vic) Pty Ltd., Cairns, Queensland North Fitzroy, Victoria Targeting engineered nanoliposomes for Darren Russell, M.D. Richard Moore therapeutic purge of HIV-1 reservoirs $5,7751 $7,5001 Fellow: Nuria Izquierdo-Useros, Ph.D. AIDS Research Institute Irsicaixa RPA Sexual Health Clinic, Royal Perth Hospital, Perth, Badalona, Spain Camperdown, New South Wales Western Australia $150,000 David Templeton, Ph.D. David Nolan $675 $5,6251 Enhanced premature self-activation of HIV-1 protease to induce apoptosis Melbourne Sexual Health Centre, Prahran Market Clinic Pty Ltd., Fellow: Kashif Sadiq, Ph.D. Carlton, Victoria Prahran, Victoria Universitat Pompeu Fabra Tim Read Norman Roth, M.B.B.S., FAChSHM 1 1 Barcelona, Spain $4,950 $6,000 $150,000 Monash Medical Centre, Sydney Sexual Health Centre, Sydney Hospital, Getting to the guts of mucosal HIV-1 transmission Clayton, Victoria Sydney, New South Wales through virus evolution Ian Woolley, M.B.B.S., FRACP Lynne Wray, M.B.B.S. 1 Fellow: Damien Tully, Ph.D. $4,125 $4,425 Massachusetts General Hospital D.A. Ellis Pty Ltd., Coffs Harbour, Hunter New England Health, Bligh Street Clinic, Boston, MA New South Wales Tamworth Sexual Health Service, Tamworth, $150,000 David Ellis, M.B.B.S. New South Wales Mechanisms of oral HIV transmission in $750 Miriam Growtowski, B.Med, FRACP $675 breast milk East Sydney Doctors, Darlinghurst, Fellow: Angela Wahl, Ph.D. New South Wales Illawarra Shoalhaven Local Health District, The University of North Carolina at Chapel Hill David Baker, B.H.B. Warrawong, New South Wales Chapel Hill, NC $7,5001 Katherine Brown, M.D. $150,000 $1,350 Holdsworth House Medical Practice, Darlinghurst, New South Wales Mark Bloch, M.D. 2014 TREAT ASIA GRANTS $6,2251 UNIVERSITY OF NEW SOUTH WALES AND AWARDS Sydney, New South Wales St. Vincent’s Hospital Sydney, Darlinghurst, Matthew G. Law, Ph.D. New South Wales 1Supported by National Institutes of Health David A. Cooper, M.D. TREAT Asia HIV Observational Database 1 and Australia HIV Observational Database cooperative agreement number U01AI069907 $6,300 $375,2181 with funds from the National Institute of Taylor Square Private Clinic, Darlinghurst, Allergy and Infectious Diseases, the National New South Wales TREAT Asia Pediatirc HIV Observational Robert Finlayson, M.B.B.S., Dip Ven Database (TApHOD) Cancer Institute, and the Eunice Kennedy 1 1 $238,185 Shriver National Institute of Child Health and $5,625 Development. Northern Territory Dept of Health & Community Cancer Studies 1 Services, Darwin, Northern Territory $58,754 Nathan Ryder, M.D. 2Supported by National Institutes Health grant Effectiveness and tolerability of hepatitis C $1,050 number 5R01HD073972 funded by the Eunice treatment in HIV co-infected patients in routine care services in Asia Kennedy Shriver National Institute of Child Health Central Coast Local Health District, Gosford, New South Wales $10,749 and Development. Debra Allen, M.B.Ch.B., Dip Med $1,425 3Supported with funds provided by the AIDS Life CAMBODIA Association. Gladstone Road Medical Centre, Highgate Hill, Queensland Our Village David Orth, M.B.B.S., Dip Ven 4Supported with funds provided by the Open New Hope for Cambodian Children, Killeen, TX $5,7001 Society Foundations. John Tucker 3 Blue Mountains Sexual Health and HIV Clinic, $53,790 5Supported with funds provided by ViiV Katoomba, New South Wales National Center for HIV/AIDS, Dermatology & Eva Jackson, FAChSHM Healthcare. STDS (NCHADS)/Cambodia National Institute $1,125 of Public Health, Phnom Penh Nepean Sexual Health Clinic, Kingswood, Vonthanak Saphonn, M.D., M.Sc., Ph.D. New South Wales TREAT Asia HIV Observational Database (TAHOD) 1 AUSTRALIA Rick Varma, M.R.C.P. $20,000 $825 TAHOD Low Intensity Transfer (TAHOD-LITE) AUSTRALIA HIV OBSERVATIONAL DATABASE $8,0001 (AHOD) SITES Sexual Health and AIDS Services (SHAIDS), Lismore, New South Wales HIV viral load testing in TAHOD patients in O’Brien, Street Practice, David Smith NCHADS participating sites 1 Adelaide, South Australia $6,450 $12,5101 William Donohue, M.B.B.S. Victorian HIV Service, The Alfred Hospital, $1,500 TREAT Asia Pediatric HIV Observational Database Melbourne, Victoria (TApHOD) Site Jennifer Hoy, M.B.B.S. $25,0003 $6,3751

65 CHINA Collection of key TB variables in Hospital Raja Perempuan Zainab II, antiretroviral therapy programs within Kelantan, Kelantan Beijing Ditan Hospital, Beijing the IeDEA consortium Nik Khairulddin Nik Yusoff, M.D. Fujie Zhang, M.D. $1,5001 TREAT Asia Pediatric HIV Observational TREAT Asia HIV Observational Database (TAHOD) Database (TApHOD) Site $16,0001 Yayasan Bali Peduli, Gianyar, Bali $7,5003 Steve Wignal Queen Elizabeth Hospital, Hong Kong HIV/AIDS outreach and prevention for women and Understanding adherence, stigma, and Man Po Lee, M.B.B.S. children in Gianyar behavioral risk factors of adolescents in TREAT Asia HIV Observational Database $12,500 TApHOD using ACASI (TAHOD), including non-communicable $4,0001/(supplement) $5001 diseases (NCD) data collection Cipto Mangunkusumo General Hospital, Jakarta $23,6601 Nia Kurniati, M.D. Hospital Likas, Kota Kinabalu TREAT Asia Pediatric HIV Observational Database Fong Siew Moy, M.D. (TApHOD) Site TREAT Asia Pediatric HIV Observational Database 3 INDIA $7,500 (TApHOD) Site $7,5003 Johns Hopkins University at B.J. Medical College Social support for HIV-infected children in Jakarta Understanding adherence, stigma, and Sassoon General Hospital, Pune 3 Amita Gupta, M.D., M.H.A. $10,000 and behavioral risk factors of adolescents Epidemiology of HIV/AIDS and associated in TApHOD using ACASI Evy Yunihastuti, M.D. $2,6001/(supplement) $3001 comorbidities in a public antiretroviral treatment TREAT Asia HIV Observational Database (ART) clinic in Pune, India (TAHOD), including non-communicable Pediatric Institute, Hospital Kuala Lumpur, $26,4601 diseases (NCD) data collection Kuala Lumpur 1 Chennai Antiviral Research and Treatment $22,750 Kamarul Razali, M.D. TREAT Asia Pediatric HIV Observational Database Clinical Research Site (CART CRS), YRG TAHOD study on the socio-economic CARE Medical Centre, VHS, Chennai (TApHOD) Site determinants of tuberculosis in Asia $7,5003 Naglingeswaran Kumarasamy, M.B.B.S., Ph.D. (supplement) $2,7501 TREAT Asia HIV Observational Database Understanding adherence, stigma, and (TAHOD), including non-communicable Effectiveness and tolerability of HCV treatment behavioral risk factors of adolescents in diseases (NCD) data collection in HIV co-infected patients: screening TApHOD using ACASI 1 $22,8601 $26,906 $2,5001/(supplement) $4001 TAHOD Low Intensity Transfer (TAHOD-LITE) Effectiveness and tolerability of HCV treatment University of Malaya, Kuala Lumpur $5,000 in HIV co-infected patients: treatment Adeeba Kamarulzaman, M.B.B.S., F.R.A.C.P., $34,035 TREAT Asia Pediatric HIV Observational FAMM, FASc Study on anal HPV infection and anal TREAT Asia HIV Observational Database (TAHOD) Database (TApHOD) Site 1 $7,5003 intraepithelial neoplasia among MSM in $20,000 Indonesia, Malaysia, and Thailand TAHOD study on the socio-economic Wide Angle Social Development 1 1 $32,010 /$17,137 determinants of tuberculosis in Asia (supp) Organization, Imphal 1 Rajkumar Nalinikanta Indonesia AIDS Coalition, Jakarta $600 Improving access to HCV treatment Ensuring equal access to health and Effectiveness and tolerability of HCV treatment $3,4764 social care support for children living with HIV in HIV co-infected patients: screening 3 $19,542 1 Delhi Network of Positive People, $14,227 New Delhi Vikas Ahuja Spiritia Foundation, Jakarta Effectiveness and tolerability of HCV treatment Hep-C test & treat demand generation Meirinda Sebayang in HIV co-infected patients: treatment in NE states of India Strengthening communities to increase support $32,515 $11,7934 for children living with and affected by HIV/AIDS $31,6313 Sungai Buloh Hospitsal, Sungai Buloh Institute of Infectious Diseases, Pune Benedict Lim Heng Sim, M.B.B.S., M.R.C.P. Sanjay Pujari, M.D. Persaudaraan Korban Napza Indonesia TREAT Asia HIV Observational Database (TAHOD) TREAT Asia HIV Observational Database (PKNI), Jakarta $15,0001 (TAHOD), including non-communicable Edo Agustian diseases (NCD) data collection Meaningful empowerment of drug users $23,0401 community on understanding hepatitis C infection, hepatitis C/HIV co-infection, and NEPAL developing viral hepatitis policy Union C, Kathmandu 4 INDONESIA $11,787 Hepatitis C awareness and advocacy event in Nepal Sanglah Hospital, Udayana University $3,5004 School of Medicine, Denpasar, Bali JAPAN Tuti Parwati Merati, M.D. Naya Goreto, Kathmandu TREAT Asia HIV Observational Database National Center for Global Health Dipu Joshi (TAHOD), including non-communicable and Medicine, Tokyo Training on HCV for people who inject drugs (PWID) diseases (NCD) data collection Shinichi Oka, M.D. $7,500 $23,0001 TREAT Asia HIV Observational Database (TAHOD) $16,0001 TAHOD Low Intensity Transfer (TAHOD-LITE) $5,0001 PHILIPPINES Ketut Dewi Kumara Wati, M.D. MALAYSIA Asian Foundation for Tropical Medicine, Inc., TREAT Asia Pediatric HIV Observational Muntinlupa City Database (TApHOD) Site Penang Hospital, Georgetown Rossana Ditangco, M.D. $7,5003 Revathy Nallusamy, M.B.B.S. TREAT Asia HIV Observational Database TREAT Asia Pediatric HIV Observational (TAHOD), including non-communicable Database (TApHOD) Site diseases (NCD) data collection $2,5003 $23,4101

76 TAHOD study on the socio-economic Praphan Phanuphak, M.D., Ph.D. Winai Ratanasuwan, M.D. determinants of tuberculosis in Asia TREAT Asia HIV Observational Database TREAT Asia HIV Observational Database (TAHOD) (supplement) $2,2501 (TAHOD), including non-communicable $4,9501 diseases (NCD) data collection Collection of key TB variables in antiretroviral $22,8901 Thai AIDS Treatment Action Group (TTAG), therapy programs within the IeDEA consortium Bangkok $8,5001/$7,8031 Collection of key TB variables in antiretroviral Paisan Suwannawong therapy programs within the IeDEA consortium Improving hepatitis C treatment access in Thailand $3,1001 $7,500 SINGAPORE Optimizing HIV treatment for children in Asia: Thai Red Cross AIDS Research Center, Bangkok Tan Tock Seng Hospital, Seng developing strategies for lifelong care Tarandeep Singh Anand 5 Oon Tek Ng, M.B.B.S., M.R.C. $100,000 Expanding Adam’s Love and Teman-Teman in Malaysia TREAT Asia HIV Observational Database (TAHOD) Nittaya Phanuphak, M.D., Ph.D. 1 $15,000 $16,000 Identifying biomarkers of anal intraepithelial TAHOD Low Intensity Transfer (TAHOD-LITE) neoplasia in Thai MSM Nittaya Phanuphak, M.D., Ph.D. 1 3 $5,0001 $90,000 /$110,363 Teman-Teman, Indonesia $50,0003 Human papillomavirus infection in perinatally HIV-infected adolescents in Asia Hepatitis C infection among Thai men who SOUTH KOREA (central lab & data manager) have sex with men and transgender women who $306,4992 access drop in centers in Thailand Yonsei University College of Medicine, Seoul $35,000 Jun Yong Choi, M.D., Ph.D. Wasana Prasitsuebsai, M.D., M.P.H. TREAT Asia HIV Observational Database TASER-Pediatrics: prospective monitoring of Enhancing communication skills for health (TAHOD), including non-communicable second-line antiretroviral therapy failure and care providers to promote early HIV testing diseases (NCD) data collection resistance in children and treatment $18,6901 $16,0003/$13,0003 $25,0001 Human papillomavirus infection in perinatally Chiang Mai University - Research Institute for HIV-infected adolescents in Asia Health Sciences, Chiang Mai TAIWAN $88,7202/(supplement) $22,0002 Romanee Chaiwarith, M.D. Kaohsiung Medical University, Kaohsiung TREAT Asia HIV Observational Database (TAHOD) Understanding adherence, stigma, and $20,0001 Yi-Ming Chen, M.D., Sc.D. behavioral risk factors of adolescents in Using the Taiwan National Health Insurance TApHOD using ACASI (data mgmt center) Virat Sirisanthana, M.D. Database to study the associations between $8,0001 TREAT Asia Pediatric HIV Observational chronic illnesses & cancer in PLHIV Database (TApHOD) Site 1 $98,277 Understanding adherence, stigma, and $15,0003 behavioral risk factors of adolescents in Taipei Veterans General Hospital, Taipei City TApHOD using ACASI TASER-Pediatrics: prospective monitoring Wing-Wai Wong, M.D. $8,4751/(supplement) $8001 of second-line antiretroviral therapy failure TREAT Asia HIV Observational Database and resistance in children (TAHOD), including non-communicable Kiat Ruxrungtham, M.D. (supplement) $6205 sdiseases (NCD) data collection Effectiveness and tolerability of HCV treatment $24,5901 in HIV co-infected patients: screening Chiangrai Prachanukroh Hospital, Chiang Rai $17,8361/(supplement) $6321 Rawiwan Hansudewechakul, M.D. TREAT Asia Pediatric HIV Observational Effectiveness and tolerability of HCV treatment THAILAND Database (TApHOD) Site in HIV co-infected patients: treatment $20,0003 HIV-NAT/Thai Red Cross AIDS Research Center, $33,010 Bangkok Understanding adherence, stigma, and Ramathibodi Hospital, Mahidol University, behavioral risk factors of adolescents in Torsak Bunupuradah, M.D. Bangkok TREAT Asia Pediatric HIV Observational TApHOD using ACASI Sasisopin Kiertiburanakul, M.D., M.H.S. $4,6503/(supplement) $8001 Database (TApHOD) Site TREAT Asia HIV Observational Database (TAHOD) 1 $15,000 $20,0001 Human papillomavirus infection in perinatally Promoting mental health interventions for HIV-infected adolescents in Asia TAHOD study on the socio-economic $69,1652/(supplement) $3,5172 perinatally HIV-infected Thai youth determinants of tuberculosis in Asia 3 $15,000 (supplement) $7001 Social Support Award for Children Reproductive health in HIV-infected and Adolescents with HIV Collection of key TB variables in antiretroviral $15,0003 female adolescents therapy programs within the IeDEA consortium 5 $116,487 $3,1001 Pacharee Kantipong, M.D. Changes in metabolic and inflammatory TREAT Asia HIV Observational Database (TAHOD) Siriraj Hospital, Mahidol University, Bangkok $13,6501 markers in HIV-positive adolescents Kulkanya Chokephaibulkit, M.D. using hormonal contraception TREAT Asia Pediatric HIV Observational Srinagarind Hospital, Khon Kaen University, 3 $12,000 Database (TApHOD) Site Khon Kaen 3 3 Stephen Kerr, Ph.D. $15,000 /(supplement) $610 Pope Kosalaraksa, M.D. Prospective validation of an adherence TASER-Pediatrics: prospective monitoring Understanding adherence, stigma, and of second-line antiretroviral therapy failure monitoring tool among HIV-infected children behavioral risk factors of adolescents in and adolescents at IeDEA sites and resistance in children TApHOD using ACASI 5 1 (supplement) $1,130 $54,076 $8,1673/(supplement) $864 Impact of genetic immune responses TASER-Pediatrics: prospective monitoring Human papillomavirus infection in perinatally of second-line antiretroviral therapy failure on neurocognition of HIV-infected children HIV-infected adolescents in Asia 1 and resistance in children $54,000 3 $80,368 $9,5003

87 Pagakrong Lumbiganon, M.D. Vietnam Network of People Living with HIV prevention and testing for GMT and capacity TREAT Asia Pediatric HIV Observational HIV (VNP+), Hanoi building at the testing center in Bukavu Database (TApHOD) Site Do Dang Dong Humanitarian Action For Health and Community $15,0003 Strengthen activity advocating for HCV testing Development (AHUSADEC) and treatment access in Vietnam Bukavu, Democratic Republic of the Congo Understanding adherence, stigma, $3,5004 $20,000 and behavioral risk factors of adolescents in TApHOD using ACASI Children’s Hospital 1, Ho Chi Minh City Increased comprehensive HIV services, ARV $4,8501/(supplement) $8001 Truong Huu Khanh, M.D. support, and adherence and career development TREAT Asia Pediatric HIV Observational Database for gay male sex workers in Kenya (TApHOD) Site Health Options For Young Men on HIV, AIDS and VIETNAM $25,0003/(supplement) $1003 STIs Nairobi, Kenya Action Central for People Living with Understanding adherence, stigma, and $20,000 HIV (ACPPlus), Hanoi behavioral risk factors of adolescents in Do Dang Dong TApHOD using ACASI Integration of HIV/STI care, treatment, and 1 Increase knowledge on hepatitis C $4,400 support services among gay men, MSM, and transgender community in Kisumu treatment among PLHIV Collection of key TB variables in antiretroviral $7,500 Men Against Aids Youth Group (MAAYGO) therapy programs within the IeDEA consortium Kisumu, Kenya 1 1 Bach Mai Hospital, Hanoi $5,000 /$5,000 $20,000 Pham Thi Thanh Thuy, M.D., Ph.D. TASER-Pediatrics: prospective monitoring AGNINEFA TREAT Asia HIV Observational Database of second-line antiretroviral therapy failure (TAHOD), including non-communicable MEN’S and resistance in children Lomé, Togo diseases (NCD) data collection $17,0003 $23,0701 $20,000 Thoa Kim Le Phan, M.D. TAHOD Low Intensity Transfer (TAHOD-LITE) Human papillomavirus infection in perinatally 1 $5,000 HIV-infected adolescents in Asia LATIN AMERICA 2 TAHOD study on the socio-economic $14,400 (funded with support from the Elton John AIDS Foundation) determinants of tuberculosis in Asia Children’s Hospital 2, Ho Chi Minh City 1 (supplement) $600 Do Chau Viet, M.D. Decrease in the barriers to HIV attention in Collection of key TB variables in antiretroviral TREAT Asia Pediatric HIV Observational trans populations and evaluation of innovative therapy programs within the IeDEA consortium Database (TApHOD) Site prevention technologies acceptability 3 3 $6,7001 $20,000 /(supplement) $3,790 Asociación de Travestis, Transexuales, y Transgeneros de Argentina Asociación Civil National Hospital of Pediatrics, Hanoi TASER-Pediatrics: prospective monitoring (ATTTA) Nguyen Van Lam, M.D., M.Sc. of second-line antiretroviral therapy failure Buenos Aires, Argentina TREAT Asia Pediatric HIV Observational and resistance in children $19,885 3 Database (TApHOD) Site $22,500 $20,0003 Friendly health center for the diagnosis, care, and Hung Vuong Hospital, Ho Chi Minh City treatment of STIs and HIV in transgender people Understanding adherence, stigma, and Nguyen Van Truong, M.D. Mesa de Trabajo Nacional – MTN as a sponsor behavioral risk factors of adolescents in Human papillomavirus infection in perinatally organization of RED TREBOL TApHOD using ACASI HIV-infected adolescents in Asia Cochabamba, Bolivia 2 $5,5001/(supplement) $8001 $21,015 $20,000 TASER-Pediatrics: prospective monitoring Worldwide Orphans Foundation, Maplewood, NJ Improving access to health services for of second-line antiretroviral therapy failure Le Ngoc Oanh, M.D. transgender people by providing a comprehensive and resistance in children Support caregivers and social workers to improve health specialist $8,5003 disclosure process to HIV-positive children Asociación Silueta X 3 $15,000 Guayaquil, Ecuador National Hospital of Tropical Diseases, Hanoi $19,980 Nguyen Van Kinh, M.D., Ph.D. TREAT Asia HIV Observational Database Project quality care in health services for the (TAHOD), including non-communicable 2014 GMT INITIATIVE AWARDS LGBT population in Honduras diseases (NCD) data collection Asociación Colectivo Violeta (ACV) $23,2301 Tegucigalpa, Honduras COMMUNITY AWARDS $20,000 TAHOD Low Intensity Transfer (TAHOD-LITE) $5,0001 Strengthening community sexual health services AFRICA for indigenous Mayan transgender women: TAHOD study on the socio-economic determinants (funded with support from the Aids Fonds of the second stage of tuberculosis in Asia Netherlands) Centro de Desarrollo e Investigación sobre 1 (supplement) $1,500 Juventud, A.C. Collection of key TB variables in antiretroviral Creating safe spaces for MSM, gay men, Campeche, Mexico therapy programs within the IeDEA consortium and transgendered individuals $18,000 $8,5001 Lesbians, Gays, Bisexuals of Botswana (LeGaBiBo), in partnership with BONELA Action on health education and HIV risk reduction Effectiveness and tolerability of HCV treatment Gaborone, Botswana for the Omeggid population in HIV co-infected patients: screening $20,000 Grupo Génesis Panamá Positivo (GGP+) $21,6681 Panama, Panama Project Access $19,955 Effectiveness and tolerability of HCV treatment Alternatives-Cameroun in HIV co-infected patients: treatment Douala, Cameroon Increase universal access for HIV and STIs in $33,010 $20,000 GMT population in Encarnacion, Paraguay SOMOSGAY Asociación Civil Asunción, Paraguay $20,000

98 HIV prevention and advocacy to improve the HIV testing behaviors among men who have sex Project SEED – syringe exchange education quality of health services for GMT in Lima with men in Tajikistan in Dayton Asociación Civil Angel Azul (ACAA) Equal Opportunities Project Director: Matt Wovrosh Lima, Peru Dushanbe, Tajikistan AIDS Resource Center Ohio $19,940 $25,000 Dayton, OH $20,0002 Sexual health and care services for GMT Factors that attribute to unknown HIV in Merida, Venezuela seropositivity and influence to HIV testing patterns African American HIV University HIV Science & Sociedad Wills Wilde, A.C. among high-risk men who have sex with men Treatment College Mérida, Venezuela Thai Red Cross AIDS Research Center Project Director: Phill Wilson $19,940 Bangkok, Thailand Black AIDS Institute $25,000 Los Angeles, CA $50,000 Opposites attract at the Instituto de Pesquisa ADVOCACY IN ACTION AWARDS Clinica Evandro Chanas, Rio de Janiero, Brazil University of New South Wales Trans in action INTERNATIONAL Comunidad de Trans Travesti Trabajadoras Sydney, Australia Sexuales Dominicana (COTRAVETD) $50,000 Support for the needs of key affected populations Santo Domingo, Dominican Republic Taking stock and looking ahead; HIV/AIDS and Project Director: Manoj Kurian $50,000 GMT in Jamaica International AIDS Society University of the West Indies Geneva, Switzerland South Africa trans* health and human rights $50,000 advocacy project Kingston, Jamaica Transgender and Intersex Africa (TIA) $10,000 Empowering civil society to effectively engage Pretoria/Tshwane, South Africa African trans* representation and visibility at with PEPFAR and key donors $50,000 ICASA 2013 project Project Director: Htun Linn Oo International HIV/AIDS Alliance Gender recognition advocacy for transgender Gender DynamiX, as a fiscal sponsor for Transitioning Africa Hove, United Kingdom people in Thailand $39,948 Thai Transgender Alliance (ThaiTGA), in Athlone, Cape Town, South Africa partnership with For-SOGI $12,310 Emergency funding to support Ugandan civil Bangkok, Thailand Global forum for MSM & HIV pre-conference and society legal action in challenging the Anti- $50,000 networking zone activities at IAC 2014 Homosexuality Act, 2014 AIDS Project Los Angeles Project Director: Wanja Muguongo My life & rights: trans health, advocacy, and The East African Sexual Health & Rights Initiative community action Los Angeles, CA $10,000 Nairobi, Kenya Health and Opportunity Network (HON) $25,000 T.Nongpue, Banglamoong, Thailand The Lancet Series: HIV in MSM Asia-Pacific $50,000 launch, November 21, 2013 Johns Hopkins University 2014 COMMUNITY OUTREACH AWARDS Baltimore, MD GENERAL GMT INITIATIVE AWARDS $45,571 Viva Cazuza Rio de Janeiro, Brazil Advocacy project ACT UP in retrospect: impact of AIDS activism on $50,000 Alternatives-Cameroun life trajectories Douala, Cameroon Research Foundation for Mental Hygiene, Inc. Pela Vidda Group $5,000 New York, NY Rio de Janeiro, Brazil $50,000 $20,000 Condom-compatible lubricant advocacy project for the LGBT population in Ghana Gay Men’s Health Crisis, Inc. Centre for Popular Education and Human Rights, New York, NY Ghana (CEPEHRG) 2014 PUBLIC POLICY $5,000 Accra, Ghana $5,000 AWARDS

Global Lubricant Access Mobilization (GLAM) 1Funded with support from the Elton John AIDS campaign Foundation. AIDS Foundation of Chicago Chicago, IL 2 $10,000 Funded with support from the Open Societies Foundations. HIV research among MSM in developing world settings – year 2 University of Pittsburgh UNITED STATES Pittsburgh, PA $167,804 Syringe exchange in the US, 2013–2014: Approaches to identifying unknown HIV-positive assessing services in a challenging environment men who have sex with men in Nairobi, Kenya Principal Investigator: Don C. Des Jarlais, Ph.D. ISHTAR MSM Mount Sinai Beth Israel New York, NY Nairobi, Kenya 1 $25,000 $90,000 Improving linkage to HIV care and services for Innovative frameworks for expanding access to HIV-positive MSM in Namibia harm reduction Society for Family Health Project Director: Suraj Madoori Windhoek, Namibia AIDS Foundation of Chicago $25,000 Chicago, IL $20,0002

109 Financial Highlights For the year ended September 30, 2014

Public Support and Revenue Public support $ 8,362,217 Special events 28,869,265 Planned giving 1,719,088 Government funding 7,391,835 Investment income and other revenue 1,418,671 Total public support and revenue $ 47,761,076

Expenses Research $ 11,853,943 TREAT Asia 6,754,069 GMT Initiative 2,388,615 Public Policy 2,234,243 Public Information 3,643,195 Total program services $ 26,874,065

Fundraising 5,232,325 Management and general 2,476,362 Total supporting services $ 7,708,687

Total expenses $ 34,582,752

Change in net assets 13,178,324 Net assets, beginning of year 31,132,023

Net assets, end of year $ 44,310,347

Statement of Financial Position

Assets Cash and investments $ 46,267,999 Accounts receivable, net 5,045,656 Prepaid expenses and other assets 4,351,616 Fixed assets, net 2,230,700 Total Assets $ 57,895,971

Liabilities Accounts payable and accrued expenses $ 2,132,495 Grants and fellowships payable, net 2,547,120 Deferred support and refundable advances 7,166,426 Other long-term liabilities 1,739,583 Total liabilities $ 13,585,624

Total net assets 44,310,347

Total liabilities and net assets $ 57,895,971

1110 Expenses

Fundraising $ 5,232,325 Management and general 2,476.362 Program 26,874,065

Total $ 34,582,752

Program Expenses

Research $ 11,853,943 TREAT Asia 6,754,069 GMT Initiative 2,388,615 Public Policy 2,234,243 Public Information 3,643,195

Total $ 26,874,065

11 12 T. Ryan Greenawalt TRUSTEES EMERITI BOARD OF TRUSTEES Managing Director Fiscal year 2014 Ramirez & Co. Arthur J. Ammann, M.D. President President, Global Strategies for HIV Prevention Chairman of the Board Harrison Street Productions Clinical Professor of Pediatrics Kenneth Cole New York, NY University of California, San Francisco Chairman San Francisco, CA Regan Hofmann Kenneth Cole Productions Policy Officer New York, NY Arnold W. Klein, M.D. Washington Liaison Office, UNAIDS Professor of Medicine/Dermatology Founding Chairman Washington, D.C. University of California, Los Angeles Mathilde Krim, Ph.D. Beverly Hills, CA Michael J. Klingensmith Adjunct Professor CEO and Publisher Mailman School of Public Health Minneapolis Star Tribune Columbia University Minneapolis, MN IN MEMORIAM New York, NY Kevin McClatchy Vice Chairman Dame Elizabeth Taylor Chairman of the Board Patricia J. Matson Founding International Chairman The McClatchy Company Senior Vice President, Communications (ret.) Ligonier, PA Sheldon W. Andelson, Esq. ABC, Inc. Mrs. Albert D. Lasker New York, NY Michele V. McNeill, Pharm.D. Jonathan M. Mann, M.D., M.P.H. Chairman Vice Chairman Maxine Mesinger McNeill Family Foundation John C. Simons Pauline Phillips Longboat Key, FL Managing Partner Natasha Richardson Corporate Fuel Partners, LLC Edward L. Milstein Allan Rosenfield, M.D. New York, NY Co-Chairman Peter Scott, Esq. Milford Management Tom Stoddard Treasurer Partner Joel D. Weisman, D.O. Wallace Sheft, C.P.A. Milstein Properties Partner (ret.) New York, NY Sheft & Co. SPECIAL APPOINTMENT Westbury, NY Cindy D. Rachofsky Philanthropist Secretary Global Fundraising Chairman Dallas, TX Mervyn F. Silverman, M.D., M.P.H. Sharon Stone President Vincent A. Roberti Mervyn F. Silverman Associates Chairman, Roberti+White, LLC Crockett, CA Washington, D.C. amfAR AMBASSADORS Managing Director Roberti Associates Global, LLC Cheyenne Jackson TRUSTEES New York, NY Janet Jackson Bill Roedy Milla Jovovich Arlen H. Andelson London, UK Liza Minnelli Andelson Properties Michelle Yeoh Los Angeles, CA Raymond F. Schinazi, Ph.D., D.Sc. Frances Winship Walters Professor Harry Belafonte Director, Laboratory of Biochemical Pharmacology President Emory University COMMITTEES OF THE BOARD Belafonte Enterprises, Inc. Decatur, GA OF TRUSTEES New York, NY Alan D. Schwartz Executive Committee David Bohnett Executive Chairman Chairman Kenneth Cole, Chair Guggenheim Partners, LLC Michael J. Klingensmith David Bohnett Foundation New York, NY Beverly Hills, CA Mathilde Krim, Ph.D. Diana L. Taylor Patricia J. Matson Zev Braun Managing Director Vincent A. Roberti President and CEO Wolfensohn Fund Management, L.P. Wallace Sheft, C.P.A. Braun Entertainment Group, Inc. New York, NY Mervyn F. Silverman, M.D., M.P.H. Beverly Hills, CA John C. Simons Kevin Wendle Jonathan S. Canno Entrepreneur Audit Committee New York, NY Paris, France Wallace Sheft, C.P.A., Chair R. Martin Chavez, Ph.D. Donald A. Capoccia John C. Simons Managing Principal BFC Partners ADJUNCT TRUSTEES Board Development Committee Brooklyn, NY Donald A. Capoccia, Co-Chair David E. Bloom, Ph.D. Patricia J. Matson, Co-Chair R. Martin Chavez, Ph.D. Clarence James Gamble Professor of Economics Arlen Andelson Chief Information Officer and Demography David Bohnett The Goldman Sachs Group, Inc. Department of Global Health and Population Bill Roedy New York, NY Harvard School of Public Health Mervyn F. Silverman, M.D., M.P.H. Boston, MA Jane B. Eisner Communications/Social Media/Marketing President Mario Stevenson, Ph.D. Regan Hofmann, Chair The Eisner Foundation Professor of Medicine Kenneth Cole Bel Air, CA Chief, Division of Infectious Diseases T. Ryan Greenawalt University of Miami Leonard M. Miller School of Patricia J. Matson Medicine Kevin McClatchy Miami, FL Vincent A. Roberti 13 Bill Roedy 12 Compensation and Organizational Development Edward Campbell, Ph.D. Anke A. Ehrhardt, Ph.D. John C. Simons, Chair Assistant Professor Director and Professor Michael J. Klingensmith School of Medicine Department of Psychiatry, Kevin McClatchy Loyola University at Chicago NY State Psychiatric Institute Columbia University Finance & Budget Alex Carballo-Dieguez, Ph.D. Michael J. Klingensmith, Chair Research Scientist and Associate Professor of Homayoon Farzadegan, Ph.D. Vincent A. Roberti Clinical Psychology Professor John C. Simons HIV Center, NY State Psychiatric Institute Department of Epidemiology Fund Development Columbia University The Johns Hopkins University Vincent A. Roberti, Chair David B. Clifford, M.D. Dianne M. Finkelstein, Ph.D. Arlen Andelson Professor Director of Biostatistics David Bohnett Department of Neurology Cancer Center Biostatistics Jonathan S. Canno Washington University School of Medicine Massachusetts General Hospital and Harvard Donald A. Capoccia Medical School T. Ryan Greenawalt C. Budd Colby, Ph.D. Cindy Rachofsky Principal Gerald Herbert Friedland, M.D. Raymond Schinazi, Ph.D., D.Sc. Colby Biomedical Consultants Professor and Director, AIDS Program Investment Committee Department of Internal Medicine Michael J. Klingensmith, Chair Grant Colfax, M.D. Yale School of Medicine R. Martin Chavez, Ph.D. Director of HIV Prevention and Research Edward L. Milstein San Francisco Department of Public Health Howard E. Gendelman, M.D. Vincent A. Roberti David T. Purtilo Professor of Pathology and Elizabeth Connick, M.D. Microbiology Wallace Sheft, C.P.A. Professor John C. Simons Department of Pathology and Microbiology Division of Infectious Diseases University of Nebraska Medical Center University of Colorado Nancy L. Haigwood, Ph.D. Deborah Jean Cotton, M.D., M.P.H. Director and Senior Scientist Professor of Medicine Division of Pathobiology and Immunology SCIENTIFIC ADVISORY Department of Medicine Oregon National Primate Research Center COMMITTEE Boston University School of Medicine Timothy Henrich, M.D. Bryan Richard Cullen, Ph.D. Instructor in Medicine, Associate Physician Professor Department of Medicine, Infectious Diseases Mario Stevenson, Ph.D. (Chair) Department of Genetics Brigham and Women’s Hospital Professor of Medicine Duke University Medical Center Chief, Division of Infectious Diseases Charles H. Hinkin, Ph.D. University of Miami Leonard M. Miller Susanna Cunningham-Rundles, Ph.D. Associate Professor School of Medicine Professor of Immunology Department of Psychiatry and Biobehavioral Department of Pediatrics Science Galit Alter, Ph.D. Cornell University Medical College University of California School of Medicine Associate Professor Department of Medicine Richard Thomas D’Aquila, M.D. David Ho, M.D. Harvard Medical School Director, Northwestern HIV Translational Scientific Director, Chief Executive Officer Research Center Aaron Diamond AIDS Research Center Deborah Anderson, Ph.D. The Howard Taylor Rickets Professor of Professor and Director Medicine, Division of Infectious Diseases, Thomas J. Hope, Ph.D. Division of Reproductive Biology Department of Medicine Professor Boston University School of Medicine Northwestern University Department of Cell and Molecular Biology Northwestern University, Feinberg School of Warren A. Andiman, M.D. Sherry Deren, Ph.D. Medicine Professor of Pediatrics, Epidemiology Director and Public Health Center for Drug Use and HIV Research Shiu-Lok Hu, Ph.D. Department of Pediatrics New York University College of Nursing Professor Yale University School of Medicine School of Pharmacy Roger Detels, M.D., M.S. University of Washington Michael Betts, Ph.D. Professor of Epidemiology Associate Professor School of Public Health Jonathan Karn, Ph.D. Department of Microbiology University of California, Los Angeles Director University of Pennsylvania School of Medicine Case Center for AIDS Research Carl W. Dieffenbach, Ph.D. Case Western Reserve University Jason Brenchley, Ph.D. Director Senior Investigator Division of AIDS (DAIDS) Vineet KewalRamani, Ph.D. Vaccine Research Center National Institute of Allergy and Infectious Chief, Model Development Section National Institute of Allergy and Infectious Diseases HIV Drug Resistance Program Diseases National Institutes of Health National Cancer Institute National Institutes of Health National Institutes of Health Daniel C. Douek, M.D., Ph.D. Dennis R. Burton, Ph.D. Chief, Human Immunology Section Richard Kornbluth, M.D., Ph.D. Professor Vaccine Research Center President and Chief Scientific Officer Department of Immunology National Institute of Allergy and Infectious Multimeric Biotherapeutics, Inc. The Scripps Research Institute Diseases National Institutes of Health Richard A. Koup, M.D. Salvatore T. Butera, D.V.M., Ph.D. Chief, Immunology Laboratory Chief Science Officer D. Peter Drotman, M.D., M.P.H. Vaccine Research Center Scripps CHAVI-ID Editor in-Chief National Institute of Allergy and Infectious The Scripps Research Institute Emerging Infectious Diseases Diseases Centers for Disease Control and Prevention National Institutes of Health

13 14 Nathaniel R. Landau, Ph.D. Donna Mildvan, M.D. Diseases Professor Chief, Division of Infectious Diseases University of California, San Diego Department of Microbiology Department of Medicine New York University School of Medicine Beth Israel Medical Center Gail Skowron, M.D. Associate Professor of Medicine Alan L. Landay, Ph.D. Jay A. Nelson, Ph.D. Department of Medicine, Division of Infectious Professor and Associate Chairman Professor and Director Diseases Department of Immunology and Microbiology Division of Pathobiology and Immunology Roger Williams Medical Center Rush-Presbyterian-St. Luke’s Medical Center Oregon Health Sciences University Leonidas Stamatatos, Ph.D. Michael Lederman, M.D. Nancy Padian, Ph.D., M.P.H. Full Member and Director of Viral Vaccines Scott R. Inkley Professor of Medicine, Executive Director Program Department of Medicine Women’s Global Health Imperative Seattle Biomedical Research Institute and Co-Director, Center for AIDS Research RTI International Case Western Reserve University Professor, Department of Obstetrics, Gynecology Ernest F. Terwilliger, Ph.D. and Reproductive Sciences Assistant Professor Tun-Hou Lee, D.Sc. and Department of Epidemiology and Biostatistics Beth Israel Deaconess Medical Center Professor of Virology University of California, San Francisco Department of Immunology and Infectious Barbara Visscher, M.D., Dr.P.H. Diseases Savita Pahwa, M.D. Professor of Epidemiology Harvard School of Public Health Director Department of Epidemiology Microbiology and Immunology University of California, Los Angeles Michael J. Leibowitz, M.D., Ph.D. University of Miami Leonard M. Miller School Professor of Medicine David Vlahov, Ph.D. Department of Molecular Genetics and Director Microbiology Tristram G. Parslow, M.D., Ph.D. Center for Urban Epidemiologic Studies University of Medicine and Dentistry of New William Patterson Timmie Professor and Chair New York Academy of Medicine Jersey-Robert Wood Johnson Medical School Department of Pathology and Laboratory Medicine Emory University School of Medicine David J. Volsky, Ph.D. Robert J. Levine, M.D. Professor and Director Professor of Medicine Matija Peterlin, M.D. Department of Pathology and Medicine Center for Interdisciplinary Research on AIDS Professor of Medicine, Microbiology and St. Luke’s-Roosevelt Hospital Center and Yale University Immunology Columbia University Department of Medicine Mathias Lichterfeld, M.D. University of California, San Francisco Steven S. Witkin, Ph.D. Assistant Professor of Medicine Professor and Director Department of Medicine Lynn Pulliam, Ph.D. Department of Obstetrics and Gynecology Massachusetts General Hospital Professor Weill Medical College of Cornell University Department of Laboratory Medicine and Medicine Judy Lieberman, M.D., Ph.D. University of California, San Francisco Peter R. Wolfe, M.D. Senior Investigator Veterans Affairs Medical Center Associate Clinical Professor Immune Disease Institute University of California, Los Angeles Professor of Pediatrics Lee Ratner, M.D., Ph.D. Harvard Medical School Professor Richard T. Wyatt, Ph.D. Department of Medicine Professor of Immunology H. Kim Lyerly, M.D. Washington University School of Medicine IAVI Center for Neutralizing Antibodies Professor in Surgery, Immunology, Pathology The Scripps Research Institute Duke Comprehensive Cancer Institute Andrew Rice, Ph.D. Duke University Medical Center Professor Department of Molecular Virology and Frank Maldarelli, M.D., Ph.D. Microbiology Investigator Baylor College of Medicine PROGRAM ADVISORY HIV DRP Host-Virus Interactions Branch National Cancer Institute Melissa Robbiani, Ph.D. COUNCIL National Institutes of Health Senior Scientist and Director of Biomedical HIV Research David M. Margolis, M.D. Center for Biomedical Research Professor of Microbiology, Medicine and Public Population Council Mervyn Silverman, M.D., M.P.H. (Chairman) Health President School of Medicine Ruth M. Ruprecht, M.D., Ph.D. Mervyn F. Silverman Associates, Inc. University of North Carolina at Chapel Hill Professor of Medicine Department of Cancer Immunology and AIDS David Bloom, Ph.D. (Co-Chairman) Martin H. Markowitz, M.D. Dana-Farber Cancer Institute and Harvard Medical Clarence James Gamble Professor of Economics Staff Investigator School and Demography Aaron Diamond AIDS Research Center Department of Global Health and Population Frederick A. Schmitt, Ph.D. Harvard School of Public Health Kenneth Hugh Mayer, M.D. Associate Professor Infectious Disease Attending & Director of HIV Departments of Neurology, Psychiatry and Mario Stevenson, Ph.D. (Co-Chairman) Prevention Research Psychology Professor of Medicine Beth Israel Deaconess Medical Center University of Kentucky Medical Center Chief, Division of Infectious Diseases Professor of Medicine University of Miami Leonard M. Miller School Harvard Medical School Gerald Schochetman, Ph.D. of Medicine Medical Research Director, Co-Chair Director, AIDS Research and Retrovirus Discovery The Fenway Institute/Fenway Health Abbott Laboratories Tim Brown, Ph.D. Senior Fellow Joseph M. McCune, M.D., Ph.D. Robert Turner Schooley, M.D. The East-West Center Professor of Medicine Academic Vice Chair Division of Experimental Medicine Professor and Head University of California, San Francisco Department of Medicine/Division of Infectious

15 14 Daria J. Hazuda, Ph.D. Vice President, Scientific Affairs for Infectious Disease Merck & Company, Inc.

Kenneth H. Mayer, M.D. Infectious Disease Attending & Director of HIV Prevention Research Beth Israel Deaconess Medical Center Visiting Professor of Medicine Harvard Medical School Medical Research Director The Fenway Institute/Fenway Health

Jeffrey L. Sturchio, Ph.D. Senior Partner Rabin Martin Visiting Scholar The Institute for Applied Economics, Global Health and the Study of Business Enterprise Johns Hopkins University

Member The Council on Foreign Relations

Phill Wilson Chief Executive Officer and President The Black AIDS Institute

MANAGEMENT GROUP

Kevin Robert Frost Chief Executive Officer Anthony Ancona Vice President and Director, Human Resources Susan J. Blumenthal, M.D., M.P.A. Senior Policy and Medical Advisor Bradley Jensen Chief Financial Officer Rowena Johnston, Ph.D. Vice President and Director, Research Jeffrey Laurence, M.D. Senior Scientific Consultant for Programs John F. Logan, Ph.D., J.D. Vice President and General Counsel Gregorio Millett, M.P.H. Vice President and Director, Public Policy Eric Muscatell Vice President, Development AnnMari Shannahan Vice President, Public Information Annette Sohn, M.D. Vice President and Director, TREAT Asia

15 amfAR, The Foundation for AIDS Research

NEW YORK 120 Wall Street, 13th Floor New York, NY 10005-3908 (212) 806-1600 (tel) (212) 806-1601 (fax)

WASHINGTON, D.C. 1150 17th Street, NW Suite 406 Washington, DC 20036-4622 (202) 331-8600 (tel) (202) 331-8606 (fax)

BANGKOK, THAILAND TREAT Asia Exchange Tower 388 Sukhumvit Road, Suite 2104 Klongtoey, Bangkok 10110 Thailand +66 (0)2 663 7561 (tel) +66 (0)2 663 7562 (fax) www.amfar.org

amfAR meets the BBB Wise Giving Alliance’s Standards for Charity Accountability.